Peptide Schedule
Pasireotide (Signifor)8 residuesFCFWKTCTEach bubble = one amino acid. Size = residue mass. Color = chemical class.Pasireotide (Signifor) Dosage Calculator
Pasireotide is a second-generation cyclohexapeptide somatostatin analog approved by the FDA in December 2012 for the treatment of Cushing's disease in adults who cannot undergo pituitary surgery or for whom surgery has failed, and subsequently in 2014 as a long-acting release (LAR) formulation for acromegaly in patients who have had an inadequate response to first-generation somatostatin analogs like octreotide and lanreotide.
300mcg · 2x Daily
Summary: Add 0mL BAC water to your 0.3mg vial. Draw to < 0.1 units on a U-100 syringe for a 300mcg dose. This vial will last 0 doses.
Cycle Planner
Pasireotide (Signifor) Pharmacokinetics
Pharmacokinetics — Active Dose Over Time
t½ = ~12 hours (subcutaneous)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only — not medical advice.
Pasireotide (Signifor) Dosing Protocol
| Level | Dose / Injection | Frequency |
|---|---|---|
| Beginner | 300mcg | 2x Daily |
| Moderate | 600mcg | 2x Daily |
| Aggressive | 900mcg | 2x Daily |
Note: Pasireotide is an FDA-approved somatostatin analog with uniquely broad receptor affinity, binding all five somatostatin receptor subtypes (SSTR1-5) with highest affinity for SSTR5. Available as Signifor (SC injection, 600-900 mcg twice daily) for Cushing's disease and Signifor LAR (IM injection, 10-40 mg every 28 days) for acromegaly. Supplied as a pre-filled solution — no reconstitution with bacteriostatic water is needed. Hyperglycemia is extremely common (up to 73% of patients) and often requires antidiabetic therapy; blood glucose monitoring is mandatory before and during treatment. This is a prescription medication and should only be used under medical supervision.
About Pasireotide (Signifor)
Pasireotide is a second-generation cyclohexapeptide somatostatin analog approved by the FDA in December 2012 for the treatment of Cushing's disease in adults who cannot undergo pituitary surgery or for whom surgery has failed, and subsequently in 2014 as a long-acting release (LAR) formulation for acromegaly in patients who have had an inadequate response to first-generation somatostatin analogs like octreotide and lanreotide. What distinguishes pasireotide from earlier somatostatin analogs is its unique receptor binding profile. While octreotide and lanreotide bind primarily to SSTR2, pasireotide has 30- to 40-fold higher affinity for SSTR5, 5-fold higher affinity for SSTR1, and 2-fold higher affinity for SSTR3, in addition to comparable SSTR2 binding. This broad-spectrum receptor engagement is clinically significant because corticotroph adenomas in Cushing's disease predominantly express SSTR5, making pasireotide the first medical therapy to directly target the pituitary tumor and normalize urinary free cortisol levels. In the pivotal Phase III trial for Cushing's disease, pasireotide 600-900 mcg SC twice daily normalized urinary free cortisol (UFC) in approximately 26% of patients at 6 months, with meaningful UFC reductions in over 50% of participants. For acromegaly, the PAOLA study demonstrated that Signifor LAR 40-60 mg monthly achieved biochemical control (GH < 2.5 mcg/L and normal IGF-1) in 31.3% of patients who had failed first-generation somatostatin analogs. The primary clinical limitation is hyperglycemia, which occurs in approximately 73% of patients and is related to pasireotide's suppression of insulin and incretin secretion through SSTR5. This often necessitates initiation or intensification of antidiabetic therapy.